← Leaderboards
Jonathan Katz
University Of Kansas Medical Center
$312,550
Attributed
$1,562,751
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $396.5K · FY2012–16$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
Funding mix
By agency
FDA$1,562,751 · 1
By mechanism
R01$1,562,751 · 1
Top collaborators
- Richard J. Barohn4 shared
- Dan Moore4 shared
- Russell H Swerdlow4 shared
- Yunxia Wang4 shared
Grant awards (4)
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis$384,448
R01 · FY2016 · FD
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis$391,431
R01 · FY2015 · FD
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis$390,367
R01 · FY2014 · FD
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis$396,505
R01 · FY2012 · FD